Definium Therapeutics: 3 Key Takeaways for Long-Term Investors
Definium Therapeutics announced positive Phase 3 clinical trial results for its lead psychiatric drug DT120 in generalized anxiety disorder and major depressive disorder, with plans to file for regulatory approval in the first half of 2027. The company holds $1.05 billion in cash to fund operations through 2030 and showed early efficacy signals for pipeline expansion into autism spectrum disorder with DT402.